Skip to content
All Brands

Hikma Pharmaceuticals USA

4 recalls on record · Last recall: Oct 20, 2026

Read the history in context

Records, not a safety rating.

Recall counts do not account for sales volume, exposure or differences in reporting. Agency records can overlap. A low count does not establish that a brand or product is safe.

View source coverage →

Severity Breakdown

Class I — Serious
0
Class II — Moderate
4
Class III — Low Risk
0

Categories

MEDICATION

Recall Timeline

Class IIFDAOct 20, 2026

Hikma Pharmaceuticals USA — CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.

Ciprofloxacin Tablets, USP, 500 mg, 100-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9928-01 Quantity: 29,085 bottles CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit. Codes: Lot# CB496A; Exp. 12/31/2026 Lot# CB497A; Exp. 12/31/2026 Lot# CB498A; Exp. 12/31/2026

Class IIFDAOct 20, 2026

Hikma Pharmaceuticals USA — CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.

Ciprofloxacin Tablets, USP, 750 mg, 50-count bottle, Rx Only, Manufactured by: Hikma Pharmaceuticals, P.O. Box 182400, Amman, 11118-Jordan, Distributed by: Hikma Pharmaceuticals USA Inc. Berkely Heights, NJ 07922, NDC 0143-9929-50 Quantity: 20,335 bottles CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit. Codes: Lot# CA083A Exp. 12/31/2026 Lot# CA084A Exp. 12/31/2026 Lot# CA085A Exp. 12/31/2026

Class IIFDAOct 6, 2026

Hikma Pharmaceuticals USA — Failed Tablet/Capsule Specifications: Failed tablet specifications for weight uniformity.

Abirtega (abiraterone acetate) USP, 250 mg, 120-count bottles, Rx only, Rx only, Mfd for: Hikma Pharmaceuticals USA Inc., Berkley Heights, NJ 07922 USA by: Arab Pharmaceuticals Manufacturing PSC PO Box 41, Sahab-Jordon, NDC 82249-011-12. Failed Tablet/Capsule Specifications: Failed tablet specifications for weight uniformity.

Class IIFDAAug 24, 2026

Hikma Pharmaceuticals USA — Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).

Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDC 76282-673-05) bottles, Rx only, Manufactured for: Exelan Pharmaceuticals, Inc., Boca Raton, FL 33432, Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228. Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).

Track Hikma Pharmaceuticals USA recalls automatically

Get an alert when a matching Hikma Pharmaceuticals USA recall turns up.

Start Free Trial